Skip to content

Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells

Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI on the Expression of FSH- and LH-receptors in Granulosa Cells

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05330130
Enrollment
6
Registered
2022-04-15
Start date
2023-07-05
Completion date
2024-06-30
Last updated
2025-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility Issues, Infertility, Infertility,Female, Ovarian Function Insufficiency

Keywords

Ovarian stimulation, Granulosa cells, Follicle Stimulating Hormone Receptor, Luteinising Hormone Receptor, Elevated progesterone

Brief summary

To study the influence of different daily rec-FSH dosages (150 IU versus 300 IU), performed in the same patient in consecutive cycles, on the relation between FSH- and LH-receptors of the granulosa cells of the growing follicle.

Detailed description

This is a prospective cross-over study. Investigators want to study the effect of different dosages of recombinant FSH in the same patient on the expression of the FSH- and LH-receptors in the granulosa cells and on the endocrine milieu in the blood and the follicular fluid. An improved understanding of the mechanism leading to progesterone elevation might initiate a change in the ovarian stimulation approach, thereby not only preventing progesterone elevation and its negative consequences on ART (Assisted Reproductive Technology) outcome, but also improving individualization of the ovarian stimulation treatment according to the patients' characteristics.

Interventions

DRUGFollitropin beta injection 150 IU

Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time: * one follicle on the morning of day 5, before the administration of the first GnRH-antagonist * one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm * two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation. Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.

DRUGFollitropin beta injection 300 IU

Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time: * one follicle on the morning of day 5, before the administration of the first GnRH-antagonist * one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm * two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation. Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.

Sponsors

Organon and Co
CollaboratorINDUSTRY
ART Fertility Clinics LLC
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 38 Years
Healthy volunteers
Yes

Inclusion criteria

* Desire to perform oocyte freezing for social fertility preservation, age 18 - 38 years * BMI of 18-32 kg/m2 * Regular menstrual cycles with a length of 24-35 days * Anti-Muellerian-Hormone levels between 1.3 - 6.25 ng/ml (Ferraretti and Gianaroli, 2014; Calzada et al., 2019)

Exclusion criteria

* Occurrence of ovarian hyperstimulation syndrome (OHSS) * Occurrence of poor ovarian response (AFC \< 5 and AMH \< 0,5ng/ml) in previous ovarian stimulation treatment (20) * Polycystic ovary syndrome (PCOS) (21)

Design outcomes

Primary

MeasureTime frame
Number of FSHR- and LHR of the GC, obtained from one follicle on the morning of day 5, before the administration of the first GnRH-antagonist, punctured during the ovarian stimulation cycle5 days
Number of FSHR- and LHR of the GC, obtained from tone follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm, punctured during the ovarian stimulation cycle1 day
Number of FSHR- and LHR of the GC, obtained from two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation, punctured during the ovarian stimulation cycle1 day
Number of FSHR- and LHR of the GC, obtained from the follicular fluid of follicles aspirated during OPU1 day

Secondary

MeasureTime frame
Level of P4 hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist5 days
Level of FSH hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist5 days
Level of LH hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist5 days
Level of E2 hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm1 day
Level of E2 hormone in the blood, on the morning of the day of final oocyte maturation1 day
Level of P4 hormone in the blood, on the morning of the day of final oocyte maturation1 day
Level of FSH hormone in the blood, on the morning of the day of final oocyte maturation1 day
Level of LH hormone in the blood, on the morning of the day of final oocyte maturation1 day
Level of E2 hormone in the blood, on the day of OPU1 day
Level of P4 hormone in the blood, on the day of OPU1 day
Level of FSH hormone in the blood, on the day of OPU1 day
Level of LH hormone in the blood, on the day of OPU1 day
Level of E2 hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist5 days
Level of P4 hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist5 days
Level of FSH hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm1 day
Level of LH hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist5 days
Level of E2 hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm1 day
Level of P4 hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm1 day
Level of FSH hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm1 day
Level of LH hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm1 day
Level of E2 hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation1 day
Level of P4 hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation1 day
Level of FSH hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation1 day
Level of LH hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation1 day
Level of E2 hormone in the follicular fluid of follicles aspirated during OPU1 day
Level of P4 hormone in the follicular fluid of follicles aspirated during OPU1 day
Level of FSH hormone in the follicular fluid of follicles aspirated during OPU1 day
Level of LH hormone in the follicular fluid of follicles aspirated during OPU1 day
Level of FSH hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist5 days
Level of LH hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm1 day
Level of P4 hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm1 day
Level of E2 hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist5 days

Countries

United Arab Emirates

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026